Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 9, 1997, Pages 1871-1875

  Wasan, Kishor M ^a   Ramaswamy, Manisha ^a   Cassidy, Shawn M ^a   Kazemi, Maryam ^a   Strobel, Frank W ^a   Thies, Robert L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LIPOSOME; LOW DENSITY LIPOPROTEIN; NYSTATIN; PHOSPHOLIPID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; HUMAN; HUMAN TISSUE; LIPID BLOOD LEVEL; PLASMA; PRIORITY JOURNAL;

EID: 0030758421     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.9.1871     Document Type: Article

References (28)

1. Dhondt, F., J. Ninane, K. De Beule, A. Dhondt, and G. Cauwenbergh. 1992. Oral candidosis: treatment with absorbable and nonabsorbable antifungal agents in children. Mycoses 35:1-8.
2. Grundy, S. M. 1990. Chapter 1, p. 1.2-1.38. In W. J. Gabello (ed.), Cholesterol and atherosclerosis: diagnosis and treatment. J. B. Lippincott Company, Philadelphia, Pa.
3. Harmony, J. A. K., A. L. Aleson, and B. M. McCarthy. 1986. Chapter 15, p. 403-430. In A. M. Scanu and A. A. Spector (ed.). Biochemistry and biology of plasma lipoproteins. Marcel Dekker, Inc., New York, N.Y.
4. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34:1345-1353.
5. Koldin, M. H., G. S. Kobayashi, J. Brajtburg, and G. Medoff. 1985. Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity in rabbits. Antimicrob. Agents Chemother. 28:144-145.
6. Krieger, M. 1983. The use of amphotericin B to detect inhibitors of cellular cholesterol biosynthesis. Anal. Biochcm. 135:383-391.
7. Lopez-Berestein, G., M. Rosenblum, and R. Mehta. 1984. Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. Cancer Drug Delivery 1:199-205.
8. Medoff, G., J. Brajtburg, and G. S. Kobayashi. 1983. Antifungal agents useful in therapy of systemic fungal infections. Annu. Rev. Pharmacol. Toxicol. 23:303-313.
9. Mehta, R. T., R. L. Hopfer, L. A. Gunner, R. L. Juliano, and G. Lopez-Berestein. 1987. Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as a therapeutic agent for systemic candidiasis. Antimicrob. Agents Chemother. 31:1897-1900.
10. Rios, A., M. Rosenblum, G. Crofoot, R. P. Lenk, A. Hayman, and G. Lopez-Berestein. 1993. Pharmacokinetics of liposomal nystatin in patients with human immunodeficiency virus infection. J. Infect. Dis. 168:153-154.
11. Schaffner, C. P., and W. Mechlinski. 1972. Polyene macrolide derivatives. II. Physical chemical properties of polyene macrolide esters and their water soluble salts. J. Antibiot. 25:259-260.
12. Selvam, M. P., R. A. Blay, S. Geyer, S. M. Buck, L. Pollock, R. E. Mayner, and J. S. Epstein. 1993. Inhibition of HIV-1 replication in H9 cells by nystatin-A compared with other antiviral agents. AIDS Res. Human Retroviruses 9:475-481.
13. Stevens, N. M., C. A. Eagle, P. B. Fisher, W. Mechlinski, and C. P. Schaffner. 1975. In vitro antiherpetic activity of water soluble amphotericin methyl ester. Arch. Virol. 48:391-394.
14. Thies, R. L., D. W. Cowens, P. R. Cullis, M. B. Bally, and L. D. Mayer. 1990. Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma. Anal. Biochem. 188:65-71.
15. Wasan, E. K., D. L. Reimer, and M. B. Bally. 1996. Plasmid DNA is protected against ultrasonic cavitation-induced damage when complexed to cationic liposomes. J. Pharm. Sci. 85:427-433.
16. Wasan, K. M., and J. S. Conklin. 1997. Enhanced amphotericin B nephrotoxicity in intensive care patients with elevated levels of low-density lipoprotein cholesterol. Clin. Infect. Dis. 24:78-80.
17. Wasan, K. M., and G. Lopez-Berestein. 1996. Characteristics of lipid-based formulations that influence their biological behavior within the plasma of patients. Clin. Infect. Dis. 23:1126-1138.
18. Wasan, K. M. 1996. Modifications in plasma lipoprotein concentration and lipid composition regulate the biological activity of hydrophobic drugs. J. Pharmacol. Toxicol. Methods 36:1-11.
19. Wasan, K. M., and R. E. Morton. 1496. Differences in lipoprotein concentration and composition modify the plasma distribution of free and liposomal annamycin. Pharm. Res. 13:462-468.
20. Wasan, K. M., and R. Perez-Soler. 1995. Distribution of free and liposomal annamycin within human plasma is regulated by plasma triglyceride concentrations but not by lipid transfer protein. J. Pharm. Sci. 84:1094-1100.
21. Wasan, K. M., and G. Lopez-Berestein. 1995. Targeted liposomes in fungi: modifying the therapeutic index of amphotericin B by its incorporation into negatively charged liposomes. J. Liposome Res. 5:883-903.
22. Wasan, K. M., and G. Lopez-Berestein. 1995. The use of liposomes for treating infectious diseases in cancer patients, p. 41-61. In S. Sugarman and R. Perez-Soler (ed.), Applications for liposomes in human malignancy: current status and future directions. R. G. Landes Company, Georgetown, Tex.
23. Wasan, K. M., R. E. Morton, M. G. Rosenblum, and G. Lopez-Berestein. 1994. Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. J. Pharm. Sci. 83:1006-1010.
24. Wasan, K. M., M. G. Rosenblum, L. Cheung, and G. Lopez-Berestein. 1994. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob. Agents Chemother. 38:223-227.
25. Wasan, K. M., G. A. Brazeau, A. Keyhani, A. C. Hayman, and G. Lopez-Berestein. 1993. Role of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob. Agents Chemother. 37:246-250.
26. Wasan, K. M., and G. Lopez-Berestein. 1993. The influence of serum lipoproteins on the pharmacokinetics and pharmacodynamics of lipophilic drugs and drug carriers. Arch. Med. Res. 24:395-401.
27. Wasan, K. M., K. Vadiei, G. Lopez-Berestein, and D. R. Luke. 1990. Pharmacokinetics, tissue distribution and toxicity of free and liposomal amphotericin B in a diabetic rat model. J. Infect. Dis. 161:562-566.
28. Wasan, K. M., et al. Unpublished data.